OraSure Technologies Helps Expand Access to Rapid HIV Testing in Recognition of National Latino AIDS Awareness Day, October 1...
13 Ottobre 2008 - 4:00PM
Business Wire
OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral
fluid diagnostics, announced today its support to expand access to
rapid HIV testing in recognition of National Latino AIDS Awareness
Day (NLAAD) taking place on October 15, 2008. The effort to help
increase opportunities for Latinos to learn their HIV status is
being executed in partnership with the Latino Commission on AIDS,
the founding organization behind the day of awareness. As part of
the effort, OraSure is providing OraQuick ADVANCE� Rapid HIV-1/2
Antibody Test kits and educational materials to the Latino
Commission on AIDS, which in turn will distribute the test kits and
materials to community testing sites and events nationwide in
conjunction with NLAAD. �Since the dawn of the epidemic, the
HIV/AIDS crisis in the U.S. has disproportionately affected the
Hispanic/Latino community and to this day the rate of HIV infection
in this community continues to rise,� said Dennis de Leon,
president of the Latino Commission on AIDS. �National Latino AIDS
Awareness Day is an opportunity to actively change this epidemic
helping members of the Latino community learn their status earlier
to help prevent the further spread of HIV. Rapid HIV tests like
OraQuick ADVANCE� � a simple, highly accurate test that can be used
with both oral fluid and blood � are helping us to reach this goal
more effectively.� Observed on Wednesday, October 15, 2008, the
sixth-annual NLAAD is a national day of awareness and prevention
against HIV/AIDS in the Latino community. With the theme, United We
Can: HIV/AIDS Stops Here! NLAAD is a call to action for Latinos to
get tested for HIV and take a stand, as a cohesive community,
against this devastating epidemic. To kick-off NLAAD 2008, the
Latino Commission on AIDS held a press conference on October 9 in
New York, where Miss Universe, Dayana Mendoza, took an OraQuick
ADVANCE� test to demonstrate her commitment to fighting HIV/AIDS.
The Latino Commission on AIDS effort to expand access to HIV
testing for Latinos involves the collective support and
participation of The Congressional Hispanic Caucus (CHC). According
to the Commission, several members of the CHC have pledged to
publicly unite in the fight against HIV/AIDS by participating in a
NLAAD event taking place in their constituency or by issuing an
official proclamation in support of the day. The U.S. Census Bureau
estimates that Latinos account for about 14% of the U.S. population
but according to the newest estimates by the Centers for Disease
Control and Prevention (released in August 2008), Latinos represent
at least 22% of new HIV/AIDS diagnoses in 2006. �We are honored to
partner with the Latino Commission on AIDS to support National
Latino AIDS Awareness Day and to help empower the Latino community
by providing access to rapid HIV testing � a critical step in
stemming the spread of the disease and helping HIV positive
individuals learn their status earlier, providing the opportunity
to protect others and a better opportunity to live a longer,
healthier life,� said Douglas A. Michels, President and Chief
Executive Officer, OraSure Technologies. National Latino AIDS
Awareness Day was created in 2003 by the Latino Commission on AIDS
and the Hispanic Federation in partnership with community based
organizations, people living with HIV/AIDS, Health Departments and
others. More than 1,000 institutions in 350 cities across the
continental United States, Puerto Rico and the U.S. Virgin Islands
are actively participating in NLAAD 2008 by forging partnerships
with like-minded organizations and hosting community events to
encourage people to seek HIV testing and counseling. OraQuick
ADVANCE� is the first and only U.S. Food and Drug Administration
approved and CLIA (Clinical Laboratory Improvements Amendments Act
of 1988) waived rapid point-of-care test that can detect antibodies
to both HIV-1 and HIV-2 in 20 minutes, using oral fluid,
finger-stick or venipuncture whole blood or plasma specimens. About
OraSure Technologies OraSure Technologies develops, manufactures
and markets oral fluid specimen collection devices using
proprietary oral fluid technologies, diagnostic products including
immunoassays and other in vitro diagnostic tests, and other medical
devices. These products are sold in the United States as well as
internationally to various clinical laboratories, hospitals,
clinics, community-based organizations and other public health
organizations, distributors, government agencies, physicians'
offices, and commercial and industrial entities. OraSure
Technologies is the leading supplier of oral-fluid collection
devices and in vitro diagnostic assays to the employment, criminal
justice, drug treatment, life insurance and public health markets
for the detection of abused drugs and the antibodies to HIV. For
more information on the Company, please go to www.orasure.com.
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Ott 2023 a Ott 2024